Predicine
Phase 3Predicine’s proprietary GeneRADAR next generation liquid biopsy platform measures cancer-associated genomic blueprint (DNA) and functional biology (RNA) in a single tube of blood to provide more accurate and in-depth insights.
Founded
2015
Focus
Diagnostics
About
Predicine’s proprietary GeneRADAR next generation liquid biopsy platform measures cancer-associated genomic blueprint (DNA) and functional biology (RNA) in a single tube of blood to provide more accurate and in-depth insights.
Funding History
3Total raised: $165M
Series C$100MOrbiMedMay 15, 2023
Series B$50MOrbiMedNov 15, 2021
Series A$15MVivo CapitalAug 15, 2020
Company Info
TypePrivate
Founded2015
LocationHayward, United States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile